BioVie Inc.
BIVI
Rank in Stocks
#29142
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the... BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Share Price
$0.9953
Last synced: 2026-11-17
Market Cap
$8.23M
Change (1 day)
-7.84%
Change (1 year)
-23.44%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade BioVie Inc. (BIVI)
Category
Healthcare
EPS for BioVie Inc. (BIVI)
EPS as of September 2026 TTM: $-2.90
According to BioVie Inc.'s latest financial reports, its current EPS (TTM) is $-2.90. At the end of 2025 the company had an EPS of $-12.12, an increase over its 2024 EPS of $-73.05.
EPS history for BioVie Inc. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.90 | -76.07% |
| 2025 | $-12.12 | -83.41% |
| 2024 | $-73.05 | -52.78% |
| 2023 | $-154.70 | 45.94% |
| 2022 | $-106.00 | -92.85% |
| 2021 | $-1.48K | 116.33% |
| 2020 | $-685.20 | 597.76% |
| 2019 | $-98.20 | -69.09% |
| 2018 | $-317.70 | 70.71% |
| 2017 | $-186.10 | 200.65% |
| 2016 | $-61.90 | 85.33% |
| 2015 | $-33.40 | -27.71% |
| 2014 | $-46.20 | 21,692.45% |
| 2013 | $-0.21 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -640.00% |
US
|
|
| $-7.07 | 143.79% |
US
|
|
| $-5.29 | 82.41% |
AU
|
|
| $12.73 | -539.04% |
BE
|
|
| $21.56 | -843.45% |
NL
|
Questions about BioVie Inc.'s earnings per share (EPS)
What is BioVie Inc.'s earnings per share (EPS)?
BioVie Inc.'s earnings per share (EPS) over the last twelve months is $-2.90, as of Sep 2026.
What was BioVie Inc.'s earnings per share (EPS) in 2025?
In 2025, BioVie Inc.'s earnings per share (EPS) was $-12.12, compared with $-73.05 in 2024.
How has BioVie Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, BioVie Inc.'s earnings per share (EPS) was highest in 2025 ($-12.12) and lowest in 2021 ($-1.48K).
How does BioVie Inc.'s earnings per share (EPS) compare with similar companies?
BioVie Inc.'s earnings per share (EPS) ($-2.90) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.